Inhibrx Biosciences, Inc. (INBX)
INBXNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$91.74
+7.22 (+8.54%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $1.35bn
- P/E
- –
- EPS, last 4 quarters
- $-8.88
- Dividend yield
- –
- Day range
- –
- 52-week range
- $57.30 to $155.29
- Average volume
- 306.5k
- Previous close
- $84.52
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $266.67, +190.7% from here
Earnings
next estimate $-2.50Next report Nov 13, 2026
Sep 2025
–
Dec 2025
–
Mar 2026
+9.3%
Jun 2026
+6.4%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$33.81m | -$30.92m | -$30.93m | -$32.15m |
| Net income | -$35.26m | -$32.83m | -$33.44m | -$36.65m |
News
8 latest- Oxbridge Re (OXBR) Q3 2026 Earnings Call TranscriptThe Motley Fool · 8 minutes ago
- GeneDx Holdings Corp. Reports Third Quarter 2026 Financial ResultsFintel · 13 minutes ago
- Texas Instruments Incorporated Consummates Issuance of $2,000,000,000 of NotesFintel · 13 minutes ago
- Take-Two Interactive Software, Inc. Reports Fiscal Second Quarter 2027 Results and Reiterates Full-Year Net Bookings Outlook of $8.0 to $8.2 billionFintel · 13 minutes ago
- HIVE Digital Technologies Ltd Q2 Loss Widens RTTNews · 19 minutes ago
- SmartRent Consensus Price Target Raised 26.88% to $2.01Fintel · 21 minutes ago
- TG Therapeutics (TGTX) Q3 2026 Earnings Call TranscriptThe Motley Fool · 21 minutes ago
- Immunovant (IMVT) Q2 2027 Earnings Call TranscriptThe Motley Fool · 21 minutes ago
The company
Inhibrx is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Inhibrx was incorporated in January 2024 as a direct, wholly-owned subsidiary of Inhibrx, Inc. Prior to the sale of Inhibrx, Inc. and the INBRX-101 program to Sanofi S.A., Inhibrx acquired certain corporate infrastructure and other assets and liabilities through a series of internal restructuring transactions effected by Inhibrx, Inc. Inhibrx, Inc. also completed a distribution to holders of its shares of common stock of 92% of the issued and outstanding shares of Inhibrx.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- inhibrx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.